PERSON
FDA Approves Axsome’s Symbravo for Acute Migraine Treatment, Overcoming 2022 Rejection
Symbravo, Axsome Therapeutics, FDA approval, acute migraine treatment, meloxicam, rizatriptan, MoSEIC technology
Senate Grills RFK Jr. on Controversial Health Stances in Contentious HHS Secretary Confirmation Hearings
Robert F. Kennedy Jr., HHS Secretary nomination, Senate confirmation hearings, vaccine skepticism, chronic disease focus, public health policy, Trump administration
Julie Kim to Succeed Christophe Weber as Takeda’s CEO in 2026
Takeda, Julie Kim, Christophe Weber, CEO succession, pharmaceutical industry, leadership transition, biopharmaceutical company
Senate Hearing for RFK Jr. Amid Strong Public Support for Vaccine Access
RFK Jr., Senate hearing, vaccine access, public support, FDA-approved vaccines, Department of Health and Human Services nomination
Secretary Rubio Expands Humanitarian Exemptions in US Foreign Aid Freeze
Marco Rubio, foreign aid freeze, humanitarian exemptions, USAID, medicine supplies, global health programs
RFK Jr. Faces Intense Scrutiny in Senate Confirmation Hearings for HHS Secretary
Robert F. Kennedy Jr., Senate confirmation hearings, Health and Human Services Secretary, Trump nominee, vaccine stance, Republican doubts
FDA Names Dr. Sara Brenner as Acting Commissioner
FDA, Acting Commissioner, Dr. Sara Brenner, Medical Devices, Food Safety
Kailera Therapeutics Appoints Jamie Coleman as Chief Commercial Officer
Kailera Therapeutics, Jamie Coleman, Chief Commercial Officer, Obesity Treatment, Zepbound, Eli Lilly
Allakos Announces Discontinuation of AK006 Program and 75% Layoffs Following Clinical Trial Failures
Allakos, AK006, clinical trial failure, layoffs, biotech, chronic spontaneous urticaria, atopic dermatitis
Allakos Discontinues AK006 Development, Cuts 75% of Workforce Amid Strategic Restructuring
Allakos, AK006, workforce reduction, strategic alternatives, Phase 1 trial failure, chronic spontaneous urticaria (CSU), biotechnology, restructuring costs.